Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorKakko, Johan
dc.contributor.authorAlho, Hannu
dc.contributor.authorBaldacchino, Alexander Mario
dc.contributor.authorMolina, Rocio
dc.contributor.authorNava, Felice Alfonso
dc.contributor.authorShaya, Gabriel
dc.date.accessioned2019-09-09T12:30:02Z
dc.date.available2019-09-09T12:30:02Z
dc.date.issued2019-08-30
dc.identifier.citationKakko , J , Alho , H , Baldacchino , A M , Molina , R , Nava , F A & Shaya , G 2019 , ' Craving in opioid use disorder : from neurobiology to clinical practice ' , Frontiers in Psychiatry , vol. 10 , 592 . https://doi.org/10.3389/fpsyt.2019.00592en
dc.identifier.issn1664-0640
dc.identifier.otherPURE: 258519676
dc.identifier.otherPURE UUID: 82244097-a3be-4935-8369-8a8811a1fab9
dc.identifier.otherScopus: 85072127535
dc.identifier.otherWOS: 000483324900001
dc.identifier.urihttp://hdl.handle.net/10023/18436
dc.descriptionFunding: Indivior UK Ltd.en
dc.description.abstractOpioid use disorder (OUD) is a major public health issue that has reached epidemic levels in some parts of the world. It is a chronic and complex neurobiological disease associated with frequent relapse to drug taking. Craving, defined as an overwhelmingly strong desire or need to use a drug, is a central component of OUD and other substance use disorders. In this review, we describe the neurobiological and neuroendocrine pathways that underpin craving in OUD and also focus on the importance of assessing and treating craving in clinical practice. Craving is strongly associated with patients returning to opioid misuse and is therefore an important treatment target to reduce the risk of relapse and improve patients’ quality of life. Opioid agonist therapies (OAT), such as buprenorphine and methadone, can significantly reduce craving and relapse risk, and it is essential that patients are treated optimally with these therapies. There is also evidence to support the benefits of non-pharmacological approaches, such as cognitive behavioral therapy and mindfulness-based interventions, as supplementary treatments to opioid agonist therapies. However, despite the positive impact of these treatments on craving, many OUD patients continue to suffer with negative affect and dysphoria. There is a clear need for further studies to progress our understanding of the neurobiological basis of craving and addiction and to identify novel therapeutic strategies as well as to optimize the use of existing treatments to improve outcomes for the growing numbers of patients affected by OUD.
dc.format.extent12
dc.language.isoeng
dc.relation.ispartofFrontiers in Psychiatryen
dc.rightsCopyright © 2019 Kakko, Alho, Baldacchino, Molina, Nava and Shaya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en
dc.subjectOpiodsen
dc.subjectCravingen
dc.subjectAddictionen
dc.subjectNegative affecten
dc.subjectMethadoneen
dc.subjectBuprenorphineen
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subject.lccRA0421en
dc.subject.lccRC0321en
dc.titleCraving in opioid use disorder : from neurobiology to clinical practiceen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.contributor.institutionUniversity of St Andrews.Population and Behavioural Science Divisionen
dc.contributor.institutionUniversity of St Andrews.Centre for Minorities Research (CMR)en
dc.identifier.doihttps://doi.org/10.3389/fpsyt.2019.00592
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record